In April 2026 the FDA "Removed" 12 Peptides From Its Restricted List. It Was Not a Win

In April 2026 the FDA "Removed" 12 Peptides From Its Restricted List. It Was Not a Win is part of the Novusyn Research editorial desk. FDA's April 15, 2026 notice moved 12 peptides out of Category 2 because nominators withdrew — a procedural exit that changed the reason compounding was blocked, not the outcome. This prerendered HTML exists so crawlers see route-specific content before the client app hydrates.

For adjacent coverage, see the news desk, clinical trials tracker, regulation tracker, guides library, and the compound directory. Novusyn Research publishes neutral, research-only reference material and does not sell compounds or provide medical advice.